Boomi Advances AI-Driven Automation with Major Announcements at Boomi World 2025
14.5.2025 15:00:00 CEST | Business Wire | Press Release
Boomi™, the leader in AI-driven automation, today announced a set of product innovations designed to accelerate and scale intelligent automation across the enterprise. These innovations — including the general availability of Boomi Agentstudio, powerful new AI agents, the addition of Boomi Data Integration (formerly Rivery) to the Boomi Enterprise Platform, and support for Model Context Protocol (MCP) — reflect the company’s commitment to business transformation through a unified, open, and AI-native platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514271179/en/
Boomi Advances AI-Driven Automation with Major Announcements at Boomi World 2025
“Today’s enterprises are overwhelmed by digital fragmentation and data sprawl,” said Steve Lucas, Chairman and CEO at Boomi. “The future belongs to organizations that can intelligently connect everything and automate anything — and Boomi is THE platform that makes it happen. With these innovations, we’re empowering our customers to move faster, work smarter, and lead in an AI-first world.”
Product Innovation Highlights
Boomi Agentstudio General Availability
Boomi Agentstudio (formerly Boomi AI Studio), the only full agent lifecycle management solution, empowers organizations to design, govern, and orchestrate all AI agents at scale within a secure, no-code environment. By combining intuitive tools with enterprise-grade governance, Boomi Agentstudio responsibly accelerates AI agent development for real-world use cases, from customer support to expense report automation.
With the general availability release, Boomi is expanding integration capabilities to include Amazon Q Business. Boomi is now an approved Data Processor enabled for all Amazon Web Services (AWS) customers — a milestone that brings powerful, enterprise-grade functionality to those building AI agents on AWS. Agentstudio's expanded governance supports centralized agent registration for Amazon Bedrock, offering observability across providers. A new Agent Step capability also allows integration developers to seamlessly embed registered agents directly into the Process Canvas.
New Boomi AI Agents
Boomi customers have already deployed over 33,000 Boomi AI Agents to unlock hyperproductivity. These intelligent software entities act on behalf of developers to automate complex tasks, streamline business processes, and accelerate application, data, and API integration — dramatically reducing time-to-value and boosting operational efficiency. The new agents include:
- Integration Advisor Agent: Autonomously review integration processes by providing actionable feedback, to improve integration efficiency and maintainability.
- API Design Agent: Rapidly design and edit APIs tailored to business and technical needs by autonomously generating OpenAPI specifications that leverage best practices for compliant and comprehensive API definitions.
- API Documentation Agent: Accelerate time-to-market and increase adoption by autonomously generating business and technical documentation from API definitions.
- Data Connector Agent: Quickly design and create data integration connectors for any REST-based data source. Connect all data within a single platform — no third-party workarounds required.
Included in the Boomi Enterprise Platform at no additional costs, these agents can be used out of the box, giving teams the flexibility to embed AI across every business process.
Model Context Protocol (MCP) Support
Model Context Protocol (MCP) has emerged as a groundbreaking open standard that enables AI agents to connect with the tools and resources they need to plan and execute tasks. The Boomi Enterprise Platform will incorporate native MCP support throughout its architecture, recognizing it as a primary protocol for process execution and automatically exposing APIs as MCP server endpoints via Boomi API Management. Boomi Agentstudio will leverage MCP to access tools seamlessly and the introduction of a new MCP gateway will enable tool aggregation and discovery, while providing enterprise grade security and governance.
Boomi Data Integration
Boomi Data Integration — formerly Rivery — is now part of the Boomi platform, unlocking powerful new data capabilities. With automated, end-to-end data pipelines, organizations can accelerate the delivery of analytics and AI-driven data products. Featuring managed data connectors, log-based change data capture (CDC), an intuitive modern UI, and enhanced observability, Boomi Data Integration enables users to seamlessly ingest, transform, and activate data from any source — faster, at greater scale, and with more precision than ever before.
A Platform Approach for a Fragmented Digital World
“As enterprises accelerate AI adoption, they require data platforms that bridge silos, streamline data management, and deliver intelligent automation,” said Matt Aslett, director of research at ISG. “Boomi’s platform approach is well placed for this opportunity — combining integration, automation, API management, and data management with AI-native capabilities to meet the challenges of digitally fragmented enterprises.”
“Boomi is uniquely positioned at the intersection of AI, enterprise data, and business process automation,” said Ed Macosky, Chief Product and Technology Officer at Boomi. “As originators of the iPaaS category — and the first integration and automation platform to introduce AI agents with full lifecycle management — Boomi continues to lead the industry forward. With today’s announcements, we’re setting a new standard for AI-driven automation, empowering organizations to move faster, operate smarter, and unlock the full value of their data.”
Additional Resources
- Learn more in this blog post
- Get the latest Boomi news here
- Follow Boomi on X (Twitter), LinkedIn, Facebook, and YouTube
About Boomi
Boomi, the leader in AI-driven automation, helps organizations around the world automate and streamline critical processes to achieve business outcomes faster. Harnessing advanced AI capabilities, the Boomi Enterprise Platform seamlessly connects systems and manages data flows with API management, integration, data management, and AI orchestration in one comprehensive solution. With over 23,000 customers globally and a network of 800+ partners, Boomi is revolutionizing the way enterprises of all sizes achieve business agility and operational excellence. Discover more at boomi.com.
© 2025 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250514271179/en/
Contacts
Media:
Kristen Walker
Global Corporate Communications
kristenwalker@boomi.com
+1-415-613-8320
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom